BridgeBio Pharma, Inc.
BBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, BridgeBio Pharma, Inc. (BBIO) is listed under Biotechnology. The company carries a $14.63B market cap, placing it firmly in the large-cap category. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Market Cap
$14.63B
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
2724.43
EPS (TTM)
$-3.56
EPS (Fwd)
$0.03
ROE
—
ROA
-26.0%
Cash
$720.2M
Total Debt
$3.37B
Free CF
-$320.3M
52W Change
39.9%
Annual Financials
Cash vs Debt
Where BBIO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, BBIO finished 3.99% above its 150-day moving average ($73.63) and 3.89% above its 200-day moving average ($73.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBIO overbought or oversold?
At the September 2, 2026 close, BBIO's RSI(14) was 26.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $720.2M in cash, though total debt stands at $3.37B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$320.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $77.6M (2022) to $502.1M (2025), reflecting a 547% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BridgeBio Pharma, Inc. and its sector.